TDMS Study 05121-07 Pathology Tables
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
Facility: Battelle Columbus Laboratory
Chemical CAS #: 6533-68-2
Lock Date: 06/01/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 70 60 70 70 70
Scheduled Sacrifice 10 10 10 10 10
Early Deaths
Natural Death 7 3 3 5 6
Moribund Sacrifice 9 10 11 7 7
Dosing Accident 2 1 1
Survivors
Terminal Sacrifice 33 36 36 37 38
Animals Examined Microscopically 61 60 60 60 61
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (61) (60) (60) (60) (60)
Perforation 1 (2%) 1 (2%)
Periesophageal Tissue, Inflammation,
Suppurative 3 (5%) 1 (2%) 1 (2%) 2 (3%)
Intestine Large, Rectum (61) (60) (60) (60) (60)
Inflammation, Chronic Active 1 (2%)
Intestine Small, Duodenum (61) (60) (59) (60) (61)
Ulcer 1 (2%)
Intestine Small, Jejunum (61) (58) (59) (60) (60)
Hyperplasia, Lymphoid 2 (3%) 2 (3%) 1 (2%) 3 (5%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Ulcer 1 (2%)
Liver (61) (60) (60) (60) (61)
Angiectasis 1 (2%) 2 (3%) 1 (2%) 1 (2%) 1 (2%)
Basophilic Focus 1 (2%) 1 (2%) 2 (3%) 4 (7%) 3 (5%)
Clear Cell Focus 1 (2%) 1 (2%)
Developmental Malformation 1 (2%)
Ectopic Tissue 1 (2%)
Eosinophilic Focus 17 (28%) 4 (7%) 10 (17%) 13 (22%) 9 (15%)
Fatty Change 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Inflammation 1 (2%)
Inflammation, Chronic Active 1 (2%)
Mixed Cell Focus 7 (11%) 1 (2%) 7 (12%) 3 (5%) 3 (5%)
Necrosis 3 (5%) 1 (2%) 2 (3%) 2 (3%)
Kupffer Cell, Pigmentation, Hemosiderin 1 (2%)
Mesentery (7) (5) (9) (4) (5)
Inflammation, Suppurative 2 (40%)
Artery, Inflammation, Chronic Active 1 (25%)
Fat, Necrosis 6 (86%) 1 (20%) 8 (89%) 2 (50%) 2 (40%)
Pancreas (61) (60) (60) (60) (61)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Atrophy 6 (10%) 4 (7%) 4 (7%) 4 (7%)
Hypertrophy 1 (2%)
Inflammation, Chronic Active 2 (3%)
Duct, Cyst 2 (3%) 3 (5%) 4 (7%) 1 (2%)
Salivary Glands (60) (60) (60) (60) (61)
Atrophy 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Duct, Hyperplasia 1 (2%)
Stomach, Forestomach (61) (60) (60) (60) (61)
Cyst 1 (2%)
Diverticulum 1 (2%)
Hyperplasia, Focal 8 (13%) 17 (28%) 3 (5%) 12 (20%) 14 (23%)
Infiltration Cellular, Plasma Cell 1 (2%)
Stomach, Glandular (61) (60) (60) (60) (61)
Erosion 2 (3%) 2 (3%)
Mineralization 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (61) (58) (60) (60) (61)
Mineralization 1 (2%)
Aorta, Inflammation, Chronic Active 1 (2%) 1 (2%)
Heart (61) (60) (60) (60) (61)
Inflammation, Chronic Active 1 (2%)
Mineralization 2 (3%) 1 (2%) 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (61) (60) (60) (60) (61)
Accessory Adrenal Cortical Nodule 1 (2%) 2 (3%) 2 (3%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 1 (2%) 1 (2%) 4 (7%) 1 (2%)
Capsule, Hyperplasia, Adenomatous 1 (2%)
Adrenal Medulla (61) (58) (59) (59) (60)
Hyperplasia 3 (5%) 1 (2%) 2 (3%)
Islets, Pancreatic (61) (60) (60) (60) (61)
Hyperplasia 1 (2%) 1 (2%) 2 (3%) 1 (2%)
Parathyroid Gland (58) (48) (48) (46) (53)
Cyst 1 (2%)
Cytoplasmic Alteration, Focal 1 (2%)
Inflammation, Chronic Active 1 (2%)
Pituitary Gland (60) (58) (57) (57) (56)
Angiectasis 1 (2%) 1 (2%)
Pars Distalis, Hyperplasia 27 (45%) 11 (19%) 15 (26%) 11 (19%) 14 (25%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (61) (60) (59) (60) (61)
Inflammation, Chronic Active 1 (2%) 1 (2%) 5 (8%) 1 (2%)
Follicular Cell, Hyperplasia 18 (30%) 5 (8%) 14 (24%) 10 (17%) 8 (13%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (58) (60) (56) (58) (58)
Duct, Ectasia 1 (2%) 1 (2%) 1 (2%)
Ovary (61) (59) (59) (59) (61)
Cyst 17 (28%) 10 (17%) 17 (29%) 12 (20%) 14 (23%)
Inflammation, Suppurative 2 (3%) 1 (2%) 1 (2%)
Mineralization 1 (2%)
Uterus (61) (60) (60) (60) (61)
Angiectasis 1 (2%) 2 (3%)
Hyperplasia, Cystic 43 (70%) 29 (48%) 37 (62%) 34 (57%) 27 (44%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (61) (60) (60) (60) (61)
Myelofibrosis 23 (38%) 18 (30%) 23 (38%) 15 (25%) 13 (21%)
Erythroid Cell, Hyperplasia 3 (5%) 2 (3%) 3 (5%) 4 (7%)
Myeloid Cell, Hyperplasia 9 (15%) 7 (12%) 5 (8%) 6 (10%) 3 (5%)
Lymph Node (6) (3) (5) (4) (3)
Bronchial, Inflammation, Chronic Active 1 (33%)
Mediastinal, Hyperplasia, Lymphoid 1 (25%)
Renal, Angiectasis 1 (20%)
Lymph Node, Mandibular (59) (57) (55) (58) (61)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%) 1 (2%)
Lymph Node, Mesenteric (60) (57) (56) (59) (58)
Hyperplasia, Lymphoid 1 (2%) 1 (2%) 1 (2%) 2 (3%)
Inflammation, Chronic Active 1 (2%)
Spleen (61) (60) (60) (60) (61)
Depletion Lymphoid 2 (3%) 1 (2%)
Hematopoietic Cell Proliferation 17 (28%) 11 (18%) 11 (18%) 17 (28%) 7 (11%)
Hyperplasia, Lymphoid 3 (5%) 2 (3%) 2 (3%) 2 (3%)
Hyperplasia, Plasma Cell 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Thymus (57) (53) (53) (56) (55)
Atrophy 3 (5%) 2 (4%) 7 (13%) 4 (7%) 3 (5%)
Inflammation, Chronic Active 1 (2%)
Mineralization 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (61) (59) (59) (60) (61)
Hyperplasia 1 (2%) 3 (5%) 2 (3%) 4 (7%)
Skin (61) (60) (60) (60) (61)
Cyst Epithelial Inclusion 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Ulcer 1 (2%)
Subcutaneous Tissue, Fibrosis, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (61) (60) (60) (60) (61)
Infarct 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Neuron, Necrosis 1 (2%) 4 (7%) 1 (2%) 2 (3%)
Peripheral Nerve (2) (2) (2)
Degeneration 2 (100%) 1 (50%) 1 (50%)
Spinal Cord (2) (2) (2) (1)
White Matter, Degeneration 1 (50%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (61) (60) (60) (60) (61)
Inflammation, Chronic Active 2 (3%) 2 (3%)
Alveolar Epithelium, Hyperplasia 1 (2%) 1 (2%)
Trachea (61) (60) (60) (60) (61)
Artery, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Internal Ear, Inflammation, Chronic Active 1 (100%)
Eye (2) (2) (2)
Degeneration 1 (50%) 1 (50%)
Cornea, Inflammation, Chronic Active 2 (100%)
Lens, Cataract 1 (50%)
Retina, Atrophy 1 (50%)
Harderian Gland (18) (10) (15) (16) (16)
Inflammation, Chronic Active 1 (7%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (61) (60) (60) (60) (61)
Cyst 1 (2%)
Infarct 1 (2%)
Inflammation, Chronic Active 1 (2%)
Mineralization 1 (2%)
Nephropathy 28 (46%) 25 (42%) 24 (40%) 27 (45%) 12 (20%)
Artery, Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
Renal Tubule, Necrosis, Acute 1 (2%)
Urinary Bladder (60) (60) (58) (59) (61)
Inflammation, Chronic Active 1 (2%)
Artery, Inflammation, Chronic Active 2 (3%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 70 60 70 70 70
Scheduled Sacrifice 10 10 10 10 10
Early Deaths
Natural Death 6 6 4 5 2
Moribund Sacrifice 4 2 7 4 7
Dosing Accident 1 1
Accidently Killed 2 1
Survivors
Terminal Sacrifice 40 41 39 39 39
Animals Examined Microscopically 60 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (60) (60) (60) (60)
Cyst 1 (2%)
Periesophageal Tissue, Inflammation,
Suppurative 1 (2%) 2 (3%) 1 (2%)
Gallbladder (59) (60) (59) (59) (58)
Inflammation, Chronic Active 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (59) (60)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Ulcer 1 (2%) 1 (2%)
Intestine Small, Ileum (59) (60) (59) (60) (58)
Amyloid Deposition 1 (2%)
Liver (60) (60) (60) (60) (60)
Amyloid Deposition 1 (2%)
Basophilic Focus 3 (5%) 1 (2%) 4 (7%) 3 (5%)
Clear Cell Focus 13 (22%) 2 (3%) 5 (8%) 3 (5%)
Eosinophilic Focus 22 (37%) 14 (23%) 8 (13%) 2 (3%)
Fatty Change 3 (5%) 5 (8%) 1 (2%)
Hematopoietic Cell Proliferation 2 (3%) 2 (3%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
Mixed Cell Focus 6 (10%) 2 (3%) 7 (12%) 9 (15%) 1 (2%)
Necrosis 1 (2%) 1 (2%) 2 (3%) 1 (2%) 3 (5%)
Bile Duct, Cyst 1 (2%)
Bile Duct, Hyperplasia 1 (2%) 1 (2%)
Hepatocyte, Hypertrophy 1 (2%)
Mesentery (5) (1) (3) (3) (2)
Infiltration Cellular, Lymphocyte 1 (33%)
Fat, Inflammation, Chronic Active 1 (20%) 1 (100%) 1 (33%) 1 (50%)
Fat, Necrosis 2 (40%) 2 (67%) 1 (33%)
Pancreas (60) (60) (60) (60) (60)
Atrophy 2 (3%) 2 (3%) 2 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Atypia Cellular 1 (2%)
Hyperplasia 1 (2%)
Necrosis 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Duct, Cyst 1 (2%) 2 (3%)
Salivary Glands (60) (60) (60) (60) (60)
Atrophy 1 (2%)
Stomach, Forestomach (60) (60) (60) (60) (60)
Hyperplasia, Focal 3 (5%) 17 (28%) 2 (3%) 3 (5%) 8 (13%)
Infiltration Cellular, Mast Cell 1 (2%)
Stomach, Glandular (60) (60) (60) (60) (60)
Dysplasia 1 (2%)
Erosion 5 (8%)
Inflammation, Chronic Active, Focal 1 (2%)
Tooth (14) (4) (5) (2)
Dysplasia 13 (93%) 3 (75%) 3 (60%) 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (60) (60) (60) (60) (59)
Aorta, Inflammation, Chronic Active 1 (2%)
Heart (60) (60) (60) (60) (60)
Inflammation, Chronic Active 2 (3%) 1 (2%)
Mineralization 2 (3%)
Artery, Inflammation, Chronic Active 1 (2%)
Artery, Mineralization 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60) (60)
Accessory Adrenal Cortical Nodule 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Hyperplasia 27 (45%) 12 (20%) 18 (30%) 20 (33%) 27 (45%)
Capsule, Hyperplasia, Adenomatous 8 (13%) 7 (12%) 2 (3%) 8 (13%) 6 (10%)
Adrenal Medulla (59) (60) (55) (60) (60)
Hyperplasia 3 (5%)
Inflammation, Chronic Active 1 (2%)
Islets, Pancreatic (60) (60) (60) (60) (60)
Hyperplasia 32 (53%) 3 (5%) 30 (50%) 12 (20%) 2 (3%)
Parathyroid Gland (56) (51) (49) (56) (52)
Hyperplasia 1 (2%)
Pituitary Gland (58) (58) (56) (55) (53)
Cyst 1 (2%) 1 (2%)
Pars Distalis, Hyperplasia 1 (2%) 1 (2%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (60) (60) (60) (60) (60)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Follicular Cell, Hyperplasia 13 (22%) 1 (2%) 15 (25%) 13 (22%) 5 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60) (60)
Granuloma Sperm 1 (2%) 2 (3%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Preputial Gland (60) (60) (60) (59) (60)
Inflammation, Chronic Active 1 (2%) 1 (2%) 2 (3%) 2 (3%) 3 (5%)
Duct, Ectasia 57 (95%) 56 (93%) 58 (97%) 56 (95%) 54 (90%)
Prostate (59) (59) (60) (60) (60)
Inflammation, Chronic Active 2 (3%) 2 (3%)
Artery, Inflammation, Chronic Active 1 (2%)
Seminal Vesicle (60) (60) (60) (60) (60)
Inflammation, Chronic Active 1 (2%) 1 (2%) 1 (2%)
Testes (60) (60) (60) (60) (60)
Atrophy 2 (3%)
Hypoplasia 1 (2%)
Interstitial Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60) (60)
Thrombosis 1 (2%)
Erythroid Cell, Hyperplasia 5 (8%) 4 (7%) 2 (3%)
Myeloid Cell, Hyperplasia 1 (2%) 1 (2%) 4 (7%) 5 (8%) 5 (8%)
Lymph Node (2) (1) (2) (3)
Lumbar, Hyperplasia, Lymphoid 1 (33%)
Mediastinal, Hyperplasia, Lymphoid 1 (50%)
Lymph Node, Mandibular (59) (59) (58) (57) (56)
Hyperplasia, Lymphoid 1 (2%) 1 (2%) 1 (2%)
Lymph Node, Mesenteric (58) (53) (56) (56) (57)
Hematopoietic Cell Proliferation 2 (3%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Hyperplasia, Plasma Cell 1 (2%)
Inflammation, Chronic Active 1 (2%)
Spleen (60) (60) (60) (60) (60)
Amyloid Deposition 1 (2%)
Angiectasis 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Depletion Lymphoid 5 (8%) 1 (2%) 1 (2%) 3 (5%)
Hematopoietic Cell Proliferation 8 (13%) 7 (12%) 12 (20%) 14 (23%) 12 (20%)
Hyperplasia, Lymphoid 1 (2%)
Thymus (51) (55) (54) (50) (50)
Atrophy 6 (12%) 5 (9%) 12 (22%) 4 (8%) 7 (14%)
Epithelial Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60) (60)
Inflammation, Chronic Active 1 (2%)
Ulcer 1 (2%)
Subcutaneous Tissue, Inflammation, Chronic
Active 2 (3%)
Subcutaneous Tissue, Lymphangiectasis 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Degeneration 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60) (60)
Hemorrhage, Acute 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Neuron, Necrosis 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60) (60)
Embolus 1 (2%)
Granuloma 1 (2%)
Hemorrhage, Acute 1 (2%)
Inflammation, Chronic Active 2 (3%) 1 (2%)
Inflammation, Suppurative 1 (2%) 1 (2%)
Pigmentation, Hemosiderin 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia 8 (13%) 5 (8%) 3 (5%) 3 (5%) 2 (3%)
Nose (60) (60) (60) (60) (60)
Hemorrhage, Acute 1 (2%)
Inflammation, Suppurative 1 (2%) 2 (3%)
Trachea (60) (60) (60) (60) (60)
Peritracheal Tissue, Hemorrhage, Acute 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05121-07 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC SCOPOLAMINE HYDROBROMIDE TRIHYDRATE Date: 04/03/96
Route: GAVAGE Time: 22:04:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 0 MG/KG 1 MG/KG 5 MG/KG 25 MG/KG
FEED RTD
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (3) (1) (3)
Degeneration 1 (33%)
Cornea, Inflammation, Chronic Active 1 (33%) 1 (100%) 1 (33%)
Cornea, Necrosis 1 (33%)
Harderian Gland (20) (18) (20) (21) (16)
Hyperplasia 1 (5%)
Inflammation, Chronic Active 2 (10%) 2 (13%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60) (60)
Cyst 6 (10%) 3 (5%) 2 (3%) 3 (5%)
Developmental Malformation 1 (2%)
Hydronephrosis 1 (2%)
Infarct 1 (2%)
Inflammation, Chronic Active 2 (3%) 2 (3%) 2 (3%)
Necrosis 1 (2%) 1 (2%)
Nephropathy 58 (97%) 49 (82%) 55 (92%) 52 (87%) 43 (72%)
Artery, Inflammation, Chronic Active 2 (3%)
Glomerulus, Amyloid Deposition 1 (2%)
Renal Tubule, Hyperplasia 2 (3%)
Urinary Bladder (60) (60) (60) (60) (59)
Inflammation, Chronic Active 2 (3%) 2 (3%) 3 (5%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------